DanCann Pharma Statistics

Total Valuation

DanCann Pharma has a market cap or net worth of SEK 7.26 million. The enterprise value is 6.04 million.

Market Cap	7.26M
Enterprise Value	6.04M

Important Dates

The last earnings date was Friday, May 23, 2025.

Earnings Date	May 23, 2025
Ex-Dividend Date	n/a

Share Statistics

DanCann Pharma has 3.99 million shares outstanding. The number of shares has increased by 2,861.85% in one year.

Current Share Class	3.99M
Shares Outstanding	3.99M
Shares Change (YoY)	+2,861.85%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	3.28%
Float	3.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.72
PB Ratio	0.41
P/TBV Ratio	1.48
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.53
EV / Sales	0.60
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.16

Current Ratio	1.16
Quick Ratio	0.43
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-8.15

Financial Efficiency

Return on equity (ROE) is -79.59% and return on invested capital (ROIC) is -44.47%.

Return on Equity (ROE)	-79.59%
Return on Assets (ROA)	-29.67%
Return on Invested Capital (ROIC)	-44.47%
Return on Capital Employed (ROCE)	-56.43%
Revenue Per Employee	2.01M
Profits Per Employee	-2.30M
Employee Count	5
Asset Turnover	0.46
Inventory Turnover	10.67

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -97.24% in the last 52 weeks. The beta is 2.06, so DanCann Pharma's price volatility has been higher than the market average.

Beta (5Y)	2.06
52-Week Price Change	-97.24%
50-Day Moving Average	1.41
200-Day Moving Average	3.39
Relative Strength Index (RSI)	42.12
Average Volume (20 Days)	33,486

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, DanCann Pharma had revenue of SEK 10.06 million and -11.50 million in losses. Loss per share was -2.33.

Revenue	10.06M
Gross Profit	-597,751
Operating Income	-10.28M
Pretax Income	-11.50M
Net Income	-11.50M
EBITDA	-7.34M
EBIT	-10.28M
Loss Per Share	-2.33

Full Income Statement

Balance Sheet

The company has 1.20 million in cash and n/a in debt, giving a net cash position of 1.20 million or 0.30 per share.

Cash & Cash Equivalents	1.20M
Total Debt	n/a
Net Cash	1.20M
Net Cash Per Share	0.30
Equity (Book Value)	17.82M
Book Value Per Share	4.46
Working Capital	475,583

Full Balance Sheet

Cash Flow

Operating Cash Flow	-9.58M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -5.94%, with operating and profit margins of -102.27% and -114.39%.

Gross Margin	-5.94%
Operating Margin	-102.27%
Pretax Margin	-114.39%
Profit Margin	-114.39%
EBITDA Margin	-73.04%
EBIT Margin	-102.27%
FCF Margin	n/a

Dividends & Yields

DanCann Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2,861.85%
Shareholder Yield	n/a
Earnings Yield	-158.51%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on February 24, 2025. It was a reverse split with a ratio of 0.001.

Last Split Date	Feb 24, 2025
Split Type	Reverse
Split Ratio	0.001

Scores

DanCann Pharma has an Altman Z-Score of 1.95 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.95
Piotroski F-Score	4